Evidence map›Paper›PMID 38666023›Full record

ArticleFrontiers in pharmacology2024

Zhiwei Huang, Xingchen Bian, Yi Li, Jiali Hu, Beining Guo, Xinyi Yang, Yi Jin, Shansong Zheng, Xinmei Wang, Cong Gao and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. In vitro activity of the novel β-lactamase inhibitor FL058 combined with meropenem against KPC- or NDM-producing enterobacterales and Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Zhiwei HuangInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Xingchen BianInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Yi LiInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Jiali HuInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Beining GuoInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Xinyi YangPhase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Yi JinPhase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Shansong ZhengQilu Pharmaceutical Co Ltd, Jinan, China.
Xinmei WangQilu Pharmaceutical Co Ltd, Jinan, China.
Cong GaoQilu Pharmaceutical Co Ltd, Jinan, China.
Jing ZhangInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Xiaojie WuPhase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Huashan Hospital · CNFudan University · CNQilu University of Technology · CNShanghai Clinical Research Center · CNLuye Pharma (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

beta-lactamase inhibitorcarbapenemase-producing Enterobacteralesin vitro modelmeropenempharmacokinetics/pharmacodynamics

Identifiers

PMID38666023
PMCPMC11043595
OpenAlexW4394722721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.